Charlotte Keywood
Nessuna posizione attualmente
Storia della carriera di Charlotte Keywood
Precedenti posizioni note di Charlotte Keywood
Società | Posizione | Inizio | Fine |
---|---|---|---|
Axovan AG
Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Direttore Tecnico/Scientifico/R&S | 01/01/2003 | 01/01/2003 |
VERNALIS | Direttore Tecnico/Scientifico/R&S | 01/01/2001 | 01/01/2001 |
ADDEX THERAPEUTICS LTD | Direttore Tecnico/Scientifico/R&S | 01/01/2004 | - |
Statistiche
Distribuzione geografica
Svizzera | 3 |
Regno Unito | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 3 |
Settori
Health Technology | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ADDEX THERAPEUTICS LTD | Health Technology |
Aziende private | 2 |
---|---|
Axovan AG
Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Commercial Services |
Ligand UK Ltd.
Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Charlotte Keywood
- Esperienza